Horizon and Perrigo in patent settlement over Pennsaid

Ireland headquartered Horizon Pharma (Nasdaq: HZNP) has entered into a settlement and license agreement with Perrigo (NYSE: PRGO) and its subsidiary Paddock Laboratories to resolve pending patent litigation involving Pennsaid (diclofenac sodium topical solution) 2%.

Under the settlement and license agreement, Horizon has granted Perrigo the non-exclusive right to market a generic diclofenac sodium topical 2% w/w solution in the USA under Perrigo's Abbreviated New Drug Application beginning January 10, 2029 or earlier under certain circumstances.

The agreement includes a stipulation by the parties requesting dismissal without prejudice of the law suits filed by Horizon in the US District Court for the District of New Jersey and the US District Court for the District of Delaware relating to the ANDA filed by Perrigo with the US Food and Drug Administration for a generic version of Pennsaid 2%.